We are live on ! Find out more
BC

Broadfin Capital Portfolio holdings

AUM $747M
1-Year Est. Return 100.56%
This Fund
S&P 500
This Quarter Est. Return
+6.13%
1 Year Est. Return
+100.56%
3 Year Est. Return
+297.65%
5 Year Est. Return
+365.91%
10 Year Est. Return
–
AUM
$1.03B
AUM Growth
-$6.85M
Cap. Flow
-$8.88M
Cap. Flow %
-0.86%
Top 10 Hldgs %
54.01%
Holding
84
New
13
Increased
14
Reduced
14
Closed
14

Top Buys

Rank Stock Value
1
ENDP
Endo International plc
ENDP
+$21.3M
2
ANGO icon
AngioDynamics
ANGO
+$13.9M
3
XENT
Intersect ENT, Inc
XENT
+$11.1M
4
MDCO
Medicines Co
MDCO
+$9.01M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$8.81M

Top Sells

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$18.7M
2
XNPT
XENOPORT, INC.
XNPT
+$7.18M
3
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$6.39M
4
ELOS
Syneron Medical Ltd
ELOS
+$6.36M
5
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$5.34M

Sector Composition

Rank Sector Weight
1 Healthcare 73.33%
2 Technology 0.11%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
51
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.79M 0.37%
693,863
+500,000
+258% +$7.97M
ANTH
52
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$3.57M 0.35%
144,334
– –
DRRX
53
DELISTED
DURECT Corp
DRRX
$3.54M 0.34%
+290,000
New +$3.72M
SCYX icon
54
SCYNEXIS
SCYX
$39.3M
$3.21M 0.31%
18,466
+9,049
+96% +$2.56M
PCRX icon
55
Pacira BioSciences
PCRX
$1.02B
$3.15M 0.31%
+93,380
New +$4.59M
ENDP
56
CALL
DELISTED
Endo International plc
ENDP
$3.12M 0.3%
+200,000
New +$4.14M
TRVN
57
DELISTED
Trevena, Inc.
TRVN
$3.1M 0.3%
787
-513
-39% -$2.41M
CFRX
58
DELISTED
ContraFect Corporation
CFRX
$1.89M 0.18%
816
-240
-23% -$609K
CDTX
59
DELISTED
Cidara Therapeutics
CDTX
$1.72M 0.17%
8,344
– –
DXTR
60
DELISTED
Dextera Surgical Inc.
DXTR
$1.55M 0.15%
+862,499
New +$1.77M
WINT
61
DELISTED
Windtree Therapeutics Inc
WINT
$1.5M 0.15%
777,797
– –
CASM
62
DELISTED
CAS Medical Systems, Inc.
CASM
$1.49M 0.15%
810,852
-1,683,682
-67% -$3.16M
PLX icon
63
Protalix BioTherapeutics
PLX
$191M
$1.3M 0.13%
202,527
-136,102
-40% -$1.09M
AIXC
64
AIxCrypto Holdings Inc
AIXC
$15.6M
$1.18M 0.11%
6
– –
PHIO icon
65
Phio Pharmaceuticals
PHIO
$12.4M
$1.17M 0.11%
8
– –
TNXP icon
66
Tonix Pharmaceuticals
TNXP
$169M
– –
0
– –
SSKN
67
DELISTED
Strata Skin Sciences
SSKN
$586K 0.06%
19,228
-938
-5% -$37.8K
PLXP
68
DELISTED
PLx Pharma Inc. Common Stock
PLXP
$444K 0.04%
5,597
-52,650
-90% -$4.56M
ARDX icon
69
Ardelyx
ARDX
$1.27B
– –
-216,180
Closed -$1.68M
IWM icon
70
PUT
iShares Russell 2000 ETF
IWM
$81.2B
– –
-1,000,000
Closed -$111M
VCYT icon
71
Veracyte
VCYT
$4.62B
– –
-97,298
Closed -$525K
ZVRA icon
72
Zevra Therapeutics
ZVRA
$740M
– –
-18,731
Closed -$4.35M
NVRO
73
CALL
DELISTED
NEVRO CORP.
NVRO
– –
-300,000
Closed -$16.9M
SPNC
74
DELISTED
Spectranetics Corp
SPNC
– –
-72,615
Closed -$1.05M
ELOS
75
DELISTED
Syneron Medical Ltd
ELOS
– –
-870,013
Closed -$6.36M
1 2
3
4

Similar funds

CBU
CIBC Bank USA Chicago, Illinois $756M AUM 24.68% 1-Year Est. Return
CONA
Capital One National Association New York $756M AUM
MP
Manikay Partners New York $893M AUM 55.39% 1-Year Est. Return
SC
Selz Capital New York $570M AUM 35.56% 1-Year Est. Return
KGACF
Kopernik Global All-Cap Fund Tampa, Florida $558M AUM
BPWA
Beacon Pointe Wealth Advisors Newport Beach, California $543M AUM 23.61% 1-Year Est. Return
TRAM
Tuscan Ridge Asset Management Chicago, Illinois $984M AUM 25.8% 1-Year Est. Return
VMI
VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

Broadfin Capital's Q2 2016 Portfolio in Review

As of Q2 2016, Broadfin Capital held 84 positions worth $1.03B, down 0.66% from $1.04B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Broadfin Capital's Q2 2016 filing shows 13 new, 14 increased, 14 reduced and 14 closed positions. Its largest new stake was Endo International plc: 1,028,802 shares worth $16M. The largest sale was NEVRO CORP., an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, up from 71% a quarter earlier, followed by Technology.

  • Broadfin Capital's largest Q2 2016 buy was Endo International plc: 1,028,802 shares worth $16M.
  • Broadfin Capital added most to AngioDynamics in Q2 2016, an estimated $13.9M increase.
  • Broadfin Capital's biggest Q2 2016 reduction was NEVRO CORP., cutting an estimated $18.7M.
  • Broadfin Capital fully exited XENOPORT, INC. in Q2 2016, selling an estimated $7.18M.
  • Broadfin Capital's ten largest holdings make up 54% of its $1.03B portfolio in Q2 2016.
  • Broadfin Capital opened 13 new positions and closed 14 in Q2 2016.
  • Broadfin Capital's portfolio value fell 0.66% quarter-over-quarter to $1.03B.

Based on Broadfin Capital's 13F filing for Q2 2016, filed 15 Aug 2016.